These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34637100)

  • 1. Dopaminergic Axons: Key Recitalists in Parkinson's Disease.
    Mishra AK; Dixit A
    Neurochem Res; 2022 Feb; 47(2):234-248. PubMed ID: 34637100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
    Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
    Duda J; Pötschke C; Liss B
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons.
    Nirenberg MJ; Vaughan RA; Uhl GR; Kuhar MJ; Pickel VM
    J Neurosci; 1996 Jan; 16(2):436-47. PubMed ID: 8551328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining.
    Ares-Santos S; Granado N; Espadas I; Martinez-Murillo R; Moratalla R
    Neuropsychopharmacology; 2014 Apr; 39(5):1066-80. PubMed ID: 24169803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.
    Honkanen EA; Saari L; Orte K; Gardberg M; Noponen T; Joutsa J; Kaasinen V
    Mov Disord; 2019 Oct; 34(10):1562-1566. PubMed ID: 31234224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preserved striatal innervation maintains motor function despite severe loss of nigral dopaminergic neurons.
    Paß T; Ricke KM; Hofmann P; Chowdhury RS; Nie Y; Chinnery P; Endepols H; Neumaier B; Carvalho A; Rigoux L; Steculorum SM; Prudent J; Riemer T; Aswendt M; Liss B; Brachvogel B; Wiesner RJ
    Brain; 2024 Sep; 147(9):3189-3203. PubMed ID: 38574200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.
    Caminiti SP; Presotto L; Baroncini D; Garibotto V; Moresco RM; Gianolli L; Volonté MA; Antonini A; Perani D
    Neuroimage Clin; 2017; 14():734-740. PubMed ID: 28409113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
    Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
    Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
    Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
    Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
    Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.
    Pinto M; Nissanka N; Peralta S; Brambilla R; Diaz F; Moraes CT
    Mol Neurodegener; 2016 Apr; 11():25. PubMed ID: 27038906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Striatal Medium Spiny Neuron Morphology Resulting from Dopamine Depletion Are Reversible.
    Witzig VS; Komnig D; Falkenburger BH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33182316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice.
    Isingrini E; Guinaudie C; C Perret L; Rainer Q; Moquin L; Gratton A; Giros B
    Sci Rep; 2017 Sep; 7(1):12432. PubMed ID: 28963508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson's Disease.
    Struzyna LA; Browne KD; Burrell JC; Vélez WJG; Wofford KL; Kaplan HM; Murthy NS; Chen HI; Duda JE; España RA; Cullen DK
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.